Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

NCT03737981 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

465

Enrollment

NIH

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Ibrutinib
BIOLOGICAL: Obinutuzumab
OTHER: Observation Activity
DRUG: Venetoclax

Sponsor

National Cancer Institute (NCI)